Distinguished in Pancreatic Cancer

Dr. Niharika B. Mettu

Oncology | Hematology
Duke Health Integrated Practice Inc
20 Duke Medicine Cir, 
Durham, NC 
Accepting New Patients
Offers Telehealth
Distinguished in Pancreatic Cancer
Duke Health Integrated Practice Inc
20 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Niharika Mettu is an Oncologist and a Hematologist in Durham, North Carolina. Dr. Mettu is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Familial Colorectal Cancer. Dr. Mettu is currently accepting new patients.

Her clinical research consists of co-authoring 24 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 9 articles and participated in 2 clinical trials in the study of Pancreatic Cancer.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
French
Hindi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Moda Health
  • EPO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
20 Duke Medicine Cir, Durham, NC 27710
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705
DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 23, 2024
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 27, 2023
Intervention Type: Drug
Study Drugs: SY-5609, Fulvestrant
Study Phase: Phase 1
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Drug
Study Drugs: Eryaspase, Gemcitabine, Abraxane, Irinotecan, 5-FU, Leucovorin
Study Phase: Phase 3
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Unknown
Publish Date: October 19, 2021
Intervention Type: Biological
Study Phase: Phase 1
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

22 Total Publications

Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 16, 2024
Similar Doctors
Distinguished in Pancreatic Cancer
Dr. Hope E. Uronis
Oncology
Distinguished in Pancreatic Cancer
Dr. Hope E. Uronis
Oncology

Duke Health Integrated Practice Inc

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hope Uronis is an Oncologist in Durham, North Carolina. Dr. Uronis is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. Her top areas of expertise are Gastroesophageal Junction Cancer, Colorectal Cancer, Pancreatic Cancer, Stomach Cancer, and Pancreaticoduodenectomy. Dr. Uronis is currently accepting new patients.

Distinguished in Pancreatic Cancer
Dr. John H. Strickler
Oncology
Distinguished in Pancreatic Cancer
Dr. John H. Strickler
Oncology

Duke Health Integrated Practice Inc

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Strickler is an Oncologist in Durham, North Carolina. Dr. Strickler is rated as an Elite provider by MediFind in the treatment of Pancreatic Cancer. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Ampullary Cancer, and Familial Colorectal Cancer. Dr. Strickler is currently accepting new patients.

Distinguished in Pancreatic Cancer
Dr. Neeraj R. Agrawal
Oncology | Hematology
Distinguished in Pancreatic Cancer
Dr. Neeraj R. Agrawal
Oncology | Hematology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English, Hindi, Marathi
See accepted insurances
Accepting New Patients
Offers Telehealth

Neeraj Agrawal is an Oncologist and a Hematologist in Durham, North Carolina. Dr. Agrawal is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. His top areas of expertise are Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, and Pancreatoblastoma. Dr. Agrawal is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mettu's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile